Contrast-Enhanced CMR in HCM What Lies Behind the Bright Light of LGE and Why it Now Matters⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology. by Maron, Martin S.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 6 , N O . 5 , 2 0 1 3
© 2 0 1 3 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 2 . 1 0 . 0 2 8E D I T O R I A L C O M M E N T
Contrast-Enhanced CMR in HCM
What Lies Behind the Bright Light of LGE and Why it Now Matters*
Martin S. Maron, MD
Boston, Massachusettss
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nOver the past decade, cardiac magnetic resonance
(CMR) has assumed an increasingly greater role in
the evaluation of patients with hypertrophic cardio-
myopathy (HCM) (1). By virtue of its high spatial
resolution, CMR provides a precise morphological
assessment of the diverse phenotypic expression of
HCM (2). This has resulted in improved diagnosis
by visualizing segmental left ventricular (LV) hy-
pertrophy not well seen by echocardiography and
identifying high-risk subgroups with scarred LV
apical aneurysms, as well as characterizing structural
abnormalities of the mitral valve and papillary
muscle (1).
See page 587
However, the capability of contrast-enhanced
CMR to identify areas of abnormal myocardial
substrate has perhaps generated the greatest interest
in clinical practice. After intravenous injection of
gadolinium, areas of hyperenhancement (i.e., late
gadolinium enhancement [LGE]) within the myo-
cardium can be identified and the amount quanti-
fied as a percentage of the total LV mass. Approx-
imately half of HCM patients demonstrate LGE,
with a diverse pattern and location, although most
commonly involving hypertrophied segments of the
LV wall (1).
This technique has now been applied to large
populations of HCM patients to define the clinical
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disclose.ignificance of LGE. Initial cross-sectional studies
onfirmed that HCM patients with LGE were at
reater risk of ventricular tachyarrhythmias on am-
ulatory monitoring compared with those without
GE (3). Subsequently, an international multi-
enter prospective study was recently completed in
hich almost 1,300 consecutive HCM patients
ere prospectively followed for 3 years after
ontrast-enhanced CMR. Extensive LGE occupy-
ng 15% of the LV myocardium was found to be
n independent predictor of sudden death (4), with
MR providing the only opportunity to identify a
ubgroup of young asymptomatic HCM patients at
ncreased risk of sudden death (by virtue of exten-
ive LGE) and therefore potential candidates for
mplantable cardioverter-defibrillator therapy (4).
These findings underscore 2 important (and re-
ated) emerging principles. CMR with LGE can
rovide unique information that directly affects
CM patient management and that the amount of
GE is clinically relevant. This is in contrast to
revious CMR studies on HCM that focused
lmost entirely on the association between a quali-
ative visual assessment of the presence of LGE and
utcome (1,5), a strategy that is not practical for
linical decision making given how common LGE
s in HCM. Therefore, if CMR is to be incorpo-
ated into the routine clinical evaluation of HCM
atients for the purposes of risk stratification, a
uantitative strategy for LGE will be required (1).
In this regard, numerous techniques have been
sed to assess LGE in HCM, including semiauto-
ated algorithms that identify high signal intensity
GE pixels in the LV wall after applying a gray-
cale threshold a number of SDs above the mean
ignal intensity within a remote region containing
ormal “nulled” myocardium (i.e., 2, 4, 5, or 6 SD)
nd the full width at half maximum (FWHM)
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598method (pixels with a signal intensity 50% of the
aximum intensity of the brightest region of hy-
erenhancement) (6). These quantification algo-
ithms were initially validated in patients with
oronary artery disease in whom lower signal inten-
ity thresholds (i.e., 2 SD) correlate well with the
patial extent of infarct tissue (7). This is related to
he fact that scar that results from a myocardial
nfarction is composed of focal, high signal inten-
ity, homogeneous hyperenhancement surrounded
y otherwise structurally normal myocardium.
However, the optimal approach to quantifying
GE in HCM is still not well defined (7). There
re a number of reasons why this is the case, but
erhaps the 3 most important issues are as follows:
) as opposed to ischemic cardiomyopathy, HCM is
haracterized by diffuse histopathological abnor-
alities involving the entire LV myocardium, in-
luding replacement fibrosis or expanded extracel-
ular matrix due to interstitial fibrosis and/or
yocyte disarray (1). This results in a gradient of
adolinium deposition in the myocardium with
ocal areas of dense concentration producing high
ignal intensity hyperenhancement and diffuse re-
ions of concentration resulting in lower signal
ntensity (7,8). 2) The limited spatial resolution of
n vivo imaging can result in partial volume effects
nd, along with inappropriate nulling and back-
round noise, can generate areas of increased signal
ntensity that appear visually as LGE but do not
epresent abnormal substrate (6,7). 3) Elucidating
recisely the histological basis of LGE in HCM
atients with normal LV function has not been
ossible due to the lack of a spontaneous HCM
nimal model (1).
As a result, it has not been possible to determine
he optimal threshold technique that provides the
losest representation of myocardial fibrosis or to
larify whether different gradients of LGE signal
ntensity correspond to different forms of fibrosis
interstitial vs. replacement). For this reason, sub-
tantial differences in the amount of LGE gener-
ted in an individual HCM patient can be present
epending on which thresholding method is used
6–8), with no consensus with respect to the
ptimal method to use in HCM. However, higher
ray-scale thresholds (6 SD) and FWHM have
ppeared to yield the closest approximation of the
xtent of LGE identified visually and the most
eproducible (6,8).
In the article by Moravsky et al. (9), the authors
rovide the first systematic evaluation correlating
istological findings with a variety of LGE quanti-fication methods in patients with HCM and normal
systolic function. The only other histopathological
correlative studies on this disease have been 2 case
reports from patients in the uncommon end-stage
phase with systolic dysfunction (10). Myocardial
tissue was obtained from 29 HCM patients at the
time of surgical myectomy, and a histopathological
analysis of these samples was undertaken to quan-
tify areas of interstitial and replacement fibrosis.
Portions of the contrast-enhanced CMR images at
the myectomy site were analyzed using a variety of
gray-scale thresholds and FWHM to determine
which provided the optimal detection for fibrosis as
derived from the histological samples.
A number of relevant observations were derived
from these data including: 1) high gray-scale
thresholds provide the best representation of total
fibrosis burden compared with lower thresholds and
the FWHM method; 2) fibrosis identified using
high gray-scale thresholds is composed of intersti-
tial and replacement fibrosis, although greater
amounts of the former than latter; and 3) with
increasing threshold levels (5 and up to 10 SD),
the specificity for identifying replacement fibrosis
versus interstitial increases.
What are the implications of these data? First,
these findings substantiate that high gray-scale
thresholds are, in fact, identifying myocardial fibro-
sis and that 5 SD could be viewed as the most
clinically relevant method for quantifying LGE in
HCM. However, the actual difference in amount of
LGE between 5 and 6 SD (or FWHM) is minimal
with substantial overlap. Second, LGE quantified
using lower gray-scale cutoffs appears to incorporate
a larger proportion of voxels with increased signal
intensity that are not representative of abnormal
histopathology, but rather noise due to image arti-
fact or suboptimal T1 inversion times, suggesting
that these methods are not optimal for quantifying
LGE in HCM (9).
One limitation of this study was the authors did
not incorporate a manual method in which a gray-
scale threshold is adjusted to define areas of visually
identified LGE. This method was used to assess the
extent of LGE in the aforementioned prospective
multicenter LGE study (4), as it correlates well with
the amount LGE quantified using high gray-scale
threshold cutoffs, has excellent reproducibility, and
is less time-consuming to perform, potentially mak-
ing this method more attractive to incorporate into
routine clinical practice.
Likewise, Moravsky et al. (9) also highlight that
the current contrast-enhanced CMR techniques
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599cannot reliably differentiate between interstitial and
replacement fibrosis. However, even though the
authors demonstrate that the specificity for detect-
ing replacement fibrosis in HCM is greater with
increasing gray-scale threshold cutoff values, even at
the very high cutoff value of 10 SD, both types of
myocardial fibrosis are present. Therefore, it is
currently not possible to determine which type of
fibrosis is more relevant with respect to generating
ventricular tachyarrhythmias in HCM. Perhaps
novel techniques such as T1 mapping will ulti-
mately improve on these limitations of late gado-
linium enhancement.
In summary, these data lend histopathological
validation to the current clinical approach to quan-hypertrophic cardiomyopathy: an inter- hancement withmethods in patients with HCM. As a result, this
information brings us a step closer to establishing
greater uniformity with respect to the most appro-
priate method to apply to HCM patients for the
purpose of quantifying LGE in this disease. Ulti-
mately, the final word will require prospective
clinical trials in which a variety of quantification
techniques can be directly compared to determine
which represents the most robust method for iden-
tifying HCM patients at high risk.
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